Market Place
Sourcing Support
CalciMedica to Present at Piper Sandler 36th Annual Conference
21 Nov 2024 //
PR NEWSWIRE
CalciMedica Announces Presentations at Upcoming Medical Meetings
20 Nov 2024 //
PR NEWSWIRE
CalciMedica Reports Q3 2024 Financial Results & Corporate Updates
13 Nov 2024 //
PR NEWSWIRE
CalciMedica Appoints Stephen Bardin as CFO
07 Nov 2024 //
PR NEWSWIRE
CalciMedica to Present CARPO Trial on Auxora in Acute Pancreatitis
30 Oct 2024 //
PR NEWSWIRE
CalciMedica Announces Pricing of Public Offering of Common Stock
30 Oct 2024 //
PR NEWSWIRE
CalciMedica to Review Phase 2b CARPO Trial Data for AP
28 Oct 2024 //
PR NEWSWIRE
CalciMedica Late-Breaker Presentation At ACG 2024 Meeting
16 Oct 2024 //
PR NEWSWIRE
CalciMedica to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
PR NEWSWIRE
CalciMedica Reports Q2 2024 Results And Provides Updates
12 Aug 2024 //
PR NEWSWIRE
CalciMedica Enrolls First Patient In Auxora Phase 2 Kidney Injury Trial
09 Jul 2024 //
PR NEWSWIRE
CalciMedica Announces Presentations at Two Upcoming Healthcare Conferences
08 Jul 2024 //
PR NEWSWIRE
CalciMedica Announces Positive Data from Phase 2b CARPO Trial of Auxora
27 Jun 2024 //
PR NEWSWIRE
CalciMedica`s Calcium Channel Inhibitor Helps Pancreatitis Patients Eat Solids
27 Jun 2024 //
FIERCE BIOTECH
CalciMedica Reports Q1 2024 Results, Clinical And Corporate Updates
13 May 2024 //
PR NEWSWIRE
CalciMedica Completes CARPO Phase 2b Acute Pancreatitis Enrollment
24 Apr 2024 //
PR NEWSWIRE
CalciMedica Presents Data from Preclinical Studies of Auxora
13 Mar 2024 //
PR NEWSWIRE
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora
28 Feb 2024 //
PR NEWSWIRE
CalciMedica Announces FDA Clearance of IND Application for Phase 2 of Auxora
13 Feb 2024 //
PR NEWSWIRE
CalciMedica to Present at the Oppenheimer 34th Annual Life Sciences Conference
07 Feb 2024 //
PR NEWSWIRE
CalciMedica Announces Private Placement of up to Approximately $55 Million
22 Jan 2024 //
PR NEWSWIRE
CalciMedica Collaborator St. Jude Hospital Presents Data from CRSPA Study
11 Dec 2023 //
PR NEWSWIRE
CalciMedica Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
CalciMedica Announces Presentation of Data from the CRSPA Study of Auxora
02 Nov 2023 //
PR NEWSWIRE
CalciMedica Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
CalciMedica Announces First Patient Enrolled in CARPO Trial of Auxora
09 Aug 2023 //
GLOBENEWSWIRE
CalciMedica Announces Relisting on Nasdaq
12 Jun 2023 //
GLOBENEWSWIRE
CalciMedica Expands Executive Team with New Appointments
23 May 2023 //
GLOBENEWSWIRE
CalciMedica Reports 1Q 2023 FYR & Provides Clinical & Corporate Updates
15 May 2023 //
GLOBENEWSWIRE
Graybug Announces Name and Trading Symbol Change
20 Mar 2023 //
GLOBENEWSWIRE
CalciMedica Announces Closing of Merger with Graybug Vision
20 Mar 2023 //
GLOBENEWSWIRE
Graybug and CalciMedica Enter into Definitive Merger Agreement
21 Nov 2022 //
GLOBENEWSWIRE
Graybug Vision Reports Financial Results for the Three and Six Months
11 Aug 2022 //
GLOBENEWSWIRE
CalciMedica Publishes Preclinical Data in EMBO Molecular Medicine for IBD
09 Aug 2022 //
PRNEWSWIRE
Graybug to Present at the 2022 OIS Retina Innovation Summit
06 Jul 2022 //
GLOBENEWSWIRE
Graybug Announces Review of Strategic Alternatives
28 Jun 2022 //
GLOBENEWSWIRE
Graybug to Present Clinical Development Plan Update for GB-102
19 May 2022 //
GLOBENEWSWIRE
Graybug Vision Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma
27 Apr 2022 //
GLOBENEWSWIRE
Graybug to Present at the 2022 ASCRS Annual Meeting
18 Apr 2022 //
GLOBENEWSWIRE
Graybug Vision Appoints Dirk Sauer to Board of Directors
13 Apr 2022 //
GLOBENEWSWIRE
Graybug Vision to Host Virtual R&D Day on March 30, 2022
21 Mar 2022 //
GLOBENEWSWIRE
Graybug Vision Reports FY 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
CalciMedica to publish Peer-Reviewed Paper of CRAC Channel Inhibitors
10 Mar 2022 //
PRNEWSWIRE
CalciMedica Initiates CARDEA-Plus Trial of Auxora in COVID-19 Pneumonia
20 Jan 2022 //
PRNEWSWIRE
Graybug Vision Announces Financial Results for Q3 Ended September 30, 2021
11 Nov 2021 //
GLOBENEWSWIRE
Graybug Vision to Participate in the American Academy of Ophthalmology 2021
01 Nov 2021 //
GLOBENEWSWIRE
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study
28 Sep 2021 //
GLOBENEWSWIRE
CalciMedica’s drug lowers mortality rate in Phase II Covid-19 trial
15 Sep 2021 //
CLINICALTRIALSARENA
CalciMedica Reports Data from AuxoraTM CARDEA, PII COVID-19 Pneumonia Trial
14 Sep 2021 //
PRNEWSWIRE
CalciMedica Publication of Preclinical Data in Journal of Immunology
09 Sep 2021 //
PRNEWSWIRE
Aveo teams with Bristol Myers after surprise FDA approval; CalciMedica up $21M
12 Mar 2021 //
ENDPTS
CalciMedica Announces $21 Million Series D Financing
11 Mar 2021 //
GLOBENEWSWIRE
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
09 Mar 2021 //
GLOBENEWSWIRE
CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker
02 Feb 2021 //
CALCIMEDIA
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD
07 Jan 2021 //
GLOBENEWSWIRE
CalciMedica Announces IDMC Recommendation to Continue Trial Evaluating Auxora™
17 Dec 2020 //
GLOBENEWSWIRE
CalciMedica Announces IDMC Recommendation to Continue Trial Evaluating Auxora™
17 Dec 2020 //
GLOBENEWSWIRE
Graybug Vision prices upsized IPO at $16, in line with the expected range
25 Sep 2020 //
SEEKING ALPHA
